Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > In today's world the paths to FDA Approval are many

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon May 31, 2023 2:16pm

82 Views

Post# 35473100

RE:RE:RE:RE:In today's world the paths to FDA Approval are many

The dreamers sure get their tail feathers ruffled when anyone disagrees with their narrative. Reminds of the liberal democrats that's burned downtown Portland a few years ago cause they didn't get their way

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing